E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Local anaesthetic for patients undergoing knee replacement surgery for arthritis |
|
E.1.1.1 | Medical condition in easily understood language |
Local anaesthetic for patients undergoing knee replacement surgery for arthritis |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To see how well a new local anaesthetic (pain killer), liposomal bupivacaine, works when compared to a standard pain killer, bupivacaine hydrochloride, that is routinely injected at the time of knee replacement surgery. |
|
E.2.2 | Secondary objectives of the trial |
To assess other aspects of patient recovery both in short and long term recovery using a range of patient-reported and objective outcome measures. To evaluate the cost effectiveness of liposomal bupivacaine compared with the current standard of care.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Unilateral primary knee replacement, including both total knee replacement (TKR) or unicompartmental knee replacement (UKR), for end stage osteoarthritis American Society of Anaesthesiologists (ASA) Grade I to III Participant is willing and able consent for themselves Male or female, aged 18 years or above. In the Investigator’s opinion, is able and willing to comply with all trial requirements.
|
|
E.4 | Principal exclusion criteria |
Allergy or intolerance to amide type local anaesthetics Objective evidence of nerve damage in the affected lower limb. Rheumatoid arthritis Any other significant disease, disorder or condition which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial. Participants who have participated in another research trial involving an investigational product in the past 6 months. Participants who have significant cognitive impairment or language issues Contra-lateral knee replacement within the trial or within 12 months prior to randomisation (If the patient is receiving staged bilateral knees, they may still participate in the trial but data will only be included from the first knee)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Quality of Recovery 40 Score at 72 hours.
Cumulative daily pain score at rest using VAS 0 to 72 hours.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
72 hours following surgery (known as day 0, 1, 2 and 3) |
|
E.5.2 | Secondary end point(s) |
To assess other markers of recovery both in the short term and long term: - Mean pain score measured using a 0-10 VAS at: baseline and evening of surgery day 0, 1, 2 and 3 following surgery. - Quality of Recovery 40 Score at baseline and evening of surgery day 0, 1, 2 and 3 following surgery. - Cumulative opioid consumption over 72 hours. Fitness for discharge against pre-defined criteria at: evening of surgery day 0, 1, 2 and 3 following surgery. - Functional outcome at baseline, 6 weeks, 6 months and 1 year (Oxford Knee Score, American Knee Society Score)
Cost utility analysis using patient-reported quality of life as the main outcome, obtained using the EuroQol EQ5D-5 Level questionnaire at baseline, 72 hours, 6 weeks, 6 months and 1 year.
Serious adverse events up to 12 months post-randomisation. Related AEs up to 30 days post-surgery. Intraoperative and inpatient complications, specifically cardiovascular or wound complications.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
72 hours following surgery; 6 weeks, 6 months & 1 year |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last assessment of the last patient randomised. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 30 |